Physician profile
Vu Hoang
NPI 1588625677
$1,256.83
in general payments reported to CMS, 2019-2025
22 companies · $588 in 2025
The $588 reported for 2025 was less than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.09 · 2023: $237 · 2024: $420 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,244.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $178.55 | 2023-2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $178.02 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $174.28 | 2025 | Onpattro |
| Medtronic, INC. | $170.97 | 2023-2024 | Corevalve Evolut R |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $74.49 | 2020-2025 | Lifevest |
| Bridgebio Pharma, INC. | $62.99 | 2025 | Attruby |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.38 | 2023-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $47.86 | 2023-2024 | Xarelto |
| Kerecis Limited | $42.95 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Glaxosmithkline, LLC. | $31.72 | 2025 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $29.91 | 2023-2024 | Farxiga |
| Esperion Therapeutics, INC. | $26.31 | 2023 | Nexletol |
| Atricure, INC. | $26.17 | 2024 | |
| Davol INC. | $26.07 | 2023 | Progel Applicator Spray Tips |
| Kiniksa Pharmaceuticals International, Plc | $21.65 | 2024 | Arcalyst |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $19.82 | 2025 | Fibryga |
| Convatec INC. | $19.47 | 2024 | |
| Amgen INC. | $17.54 | 2023 | Repatha |
| Angiodynamics, INC. | $16.05 | 2023 | Angiovac |
| Actelion Pharmaceuticals US, INC. | $14.78 | 2024 | Opsumit, Uptravi |
| Kls-Martin L.P. | $14.77 | 2024 | |
| Edwards Lifesciences Corporation | $14.08 | 2025 | Konect Resilia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vu Hoang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.